Early Clinical Data and Potential Clinical Utility of Novel Histone Deacetylase Inhibitors in Prostate Cancer
- 1 September 2005
- journal article
- Published by Elsevier BV in Clinical Prostate Cancer
- Vol. 4 (2), 83-85
- https://doi.org/10.1016/s1540-0352(11)70115-9
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTSAnnual Review of Pharmacology and Toxicology, 2005
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or LymphomaJournal of Clinical Oncology, 2005
- Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and TreatmentJNCI Journal of the National Cancer Institute, 2005
- The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584Cancer Research, 2004
- Histone-deacetylase inhibitors: novel drugs for the treatment of cancerNature Reviews Drug Discovery, 2002
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumorsProceedings of the National Academy of Sciences of the United States of America, 1999